Charles Finsterwald

Chief Scientific Officer, Co-founder at GliaPharm SA

Lausanne, Vaud, Switzerland

About

Experience

  • Chief Scientific Officer, Co-founder at GliaPharm SA
    Jul 2016 - Present · 10 yrs 1 mo

    GliaPharm is a Swiss biotech that develops innovative therapeutic strategies for neurodegenerative diseases by targeting glial cells in the brain. More info on www.gliapharm.com

  • Senior Scientist at EPFL (École polytechnique fédérale de Lausanne)
    Jun 2014 - Nov 2017 · 3 yrs 6 mos

    Scientist in the Laboratory of Neuroenergetics and Cellular Dynamics (LNDC), EPFL, Lausanne, Switzerland

  • Postdoctoral Research Scientist at New York University
    Apr 2012 - Mar 2014 · 2 yrs

    Postdoctoral research scientist in Prof. Alberini's laboratory, New York University, Center for Neural Science. Modulation of stress on the molecular mechanisms underlying long-term memory

  • Postdoctoral Research Scientist at Center for Psychiatric Neuroscience, Cery Hospital
    Jul 2011 - Mar 2012 · 9 mos

    Postdoctoral research scientist at the Center for Psychiatric Neuroscience, Cery Hospital Epigenetic and transcriptional regulations by neurotrophic factors in developing cortical neurons.

  • University of Lausanne (5 yrs 5 mos)
    • Research Assistant, PhD candidate
      Jul 2007 - Jun 2011 · 4 yrs

      Graduate student Dr. Martin's laboratory, Lemanic Neuroscience Doctoral School, University of Lausanne Regulation of dendritic development by neurotrophic factors

    • Scientific Collaborator
      Mar 2007 - Dec 2007 · 10 mos

      Presentation of scientific activities to general audience

    • Research Assistant
      Feb 2006 - Feb 2007 · 1 yr 1 mo

      Undergrad student, Departement of Biochemistry/World Health Organization and Immunology Research Training Center (WHO-IRTC), University of Lausanne, Switzerland Role of IL-23 and IL-17 in the development of Th1/Th2 responses of mice infected with L.major